Jideytro positive data for ROS1-positive NSCLC
GSK announced positive data from the ARROS-1 trial for Jideytro (zidesamtinib) in first-line ROS1-positive NSCLC, showing 94% ORR, 90% 12-month PFS, and 70% brain metastasis clearance. The company plans a US regulatory submission in 2026. GSK acquired Jideytro via its acquisition of Nuvalent, Inc.
How this was made
The 30-second read
Why it matters
The trial results provide a strong basis for a supplemental NDA, potentially increasing GSK's oncology revenue outlook.
Market read
New data could drive short‑term GSK stock movement and influence sector peers.
What to watch
The data are from a single-arm trial; confirmatory Phase III results are still needed.
Background
GSK's zidesamtinib is already FDA‑approved for post‑TKI ROS1 NSCLC; this data aims to expand to first‑line use.
Ticker impact
GSK announced positive Phase I/II ARROS-1 trial data for zidesamtinib in first-line ROS1-positive NSCLC, supporting a supplemental NDA filing.
Potential modest upside as investors price in expanded indication and upcoming FDA submission.
Phase I/II data with 94% ORR and high CNS activity are material new information for a large pharma, likely to attract analyst upgrades.
Market effects
Positive ROS1 data could lift peer biotech stocks developing targeted lung cancer therapies.
UK-listed GSK may see increased investor interest in Europe.
Adds to broader optimism in oncology drug development worldwide.
Counterpoint
If regulatory scrutiny intensifies or CNS safety concerns emerge, the stock could face downside.
Key entities
- CompanyGSK plc
Global biopharma announcing trial data.
- DrugZidesamtinib (Jideytro)
ROS1 tyrosine kinase inhibitor under development.
